Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Initial clinical studies with bruceantin.

A Y Bedikian, M Valdivieso, G P Bodey

    Cancer Treatment Reports
    |November 1, 1979
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma.

    Annals of oncology : official journal of the European Society for Medical Oncology·2010
    Same author

    Phase II trial of imatinib mesylate in patients with metastatic melanoma.

    British journal of cancer·2008
    Same author

    Emil J Freireich: a pioneer of modern oncology (interview by Sue Silver).

    The Lancet. Oncology·2002
    Same author

    Clinical research today and tomorrow.

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2002
    Same author

    Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long- term survival.

    Leukemia & lymphoma·2001
    Same author

    "T-cell-rich B-cell lymphoproliferative disorder" of the bone marrow.

    Leukemia & lymphoma·2001

    This phase I clinical study evaluated bruceantin in advanced solid tumors. The drug showed dose-limiting hypotension and moderate hematologic toxicity, with no observed tumor regressions.

    Area of Science:

    • Oncology
    • Clinical Pharmacology

    Background:

    • Bruceantin is an antineoplastic agent investigated for cancer treatment.
    • Phase I studies are crucial for determining the safety and maximum tolerated dose of new drugs.

    Purpose of the Study:

    • To evaluate the toxicity and efficacy of bruceantin in patients with advanced solid tumors.
    • To determine the dose-limiting toxic effects and establish a recommended dose for further studies.

    Main Methods:

    • A phase I clinical trial involving 66 patients with various advanced solid tumors.
    • Dose escalation from 0.2 mg/m2/day to 4.5 mg/m2/day, with treatment cycles repeated every two weeks.
    • Monitoring for adverse events, including toxicity and tumor response.

    Main Results:

    Related Experiment Videos

    • Hypotension was identified as the dose-limiting toxicity, characterized by delayed and cumulative effects, particularly in patients with pre-existing liver dysfunction.
    • Common adverse events at higher doses included nausea, vomiting, and fever. Hematologic toxicity, primarily thrombocytopenia, was moderate and exacerbated by hepatic and renal impairment.
    • No objective tumor regressions were observed during the study.

    Conclusions:

    • The recommended dose for bruceantin in phase II studies is 3.5 mg/m2/day for 5 days.
    • Bruceantin exhibits dose-limiting hypotension and moderate hematologic toxicity, necessitating careful patient selection and monitoring, especially in those with impaired liver or kidney function.